There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CHRO is 1.54M and currently, short sellers hold a 2.06% ratio of that float. The average trading volume of CHRO on October 21, 2024 was 109.39K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CHRO) stock’s latest price update
Chromocell Therapeutics Corp. (AMEX: CHRO)’s stock price has gone decline by -9.62 in comparison to its previous close of 0.77, however, the company has experienced a 22.88% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-16 that FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) — Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024.
CHRO’s Market Performance
Chromocell Therapeutics Corp. (CHRO) has experienced a 22.88% rise in stock performance for the past week, with a -20.14% drop in the past month, and a -35.60% drop in the past quarter. The volatility ratio for the week is 29.72%, and the volatility levels for the past 30 days are at 20.99% for CHRO. The simple moving average for the past 20 days is -2.13% for CHRO’s stock, with a -57.65% simple moving average for the past 200 days.
CHRO Trading at -13.18% from the 50-Day Moving Average
After a stumble in the market that brought CHRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.41% of loss for the given period.
Volatility was left at 20.99%, however, over the last 30 days, the volatility rate increased by 29.72%, as shares sank -18.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.59% upper at present.
During the last 5 trading sessions, CHRO rose by +22.88%, in comparison to the 20-day moving average, which settled at $0.7106. In addition, Chromocell Therapeutics Corp. saw -85.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CHRO starting from Malamut Richard, who purchase 10,400 shares at the price of $0.94 back on Sep 12 ’24. After this action, Malamut Richard now owns 91,565 shares of Chromocell Therapeutics Corp., valued at $9,825 using the latest closing price.
Francis Knuettel II, the CEO, Pres., CFO, Treas & Secty of Chromocell Therapeutics Corp., purchase 3,500 shares at $0.97 during a trade that took place back on Sep 13 ’24, which means that Francis Knuettel II is holding 547,710 shares at $3,395 based on the most recent closing price.
Stock Fundamentals for CHRO
The total capital return value is set at 48.59.
Based on Chromocell Therapeutics Corp. (CHRO), the company’s capital structure generated 1.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.5. The debt to equity ratio resting at -8.7. The interest coverage ratio of the stock is -9.54.
Currently, EBITDA for the company is -6.86 million with net debt to EBITDA at 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
In conclusion, Chromocell Therapeutics Corp. (CHRO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
